Crescita Therapeutics Acquired by ClinActiv in $14.9M Deal, Goes Private

By Stephanie Kelly

LAVAL, Québec – May 20, 2026 – Crescita Therapeutics Inc. is set to disappear from the public markets after obtaining a final court order approving its acquisition by the privately-held ClinActiv Holdings Inc. The all-cash deal, valued at approximately $14.9 million, marks a significant strategic move in the consolidating dermatology sector and will see the Canadian company go private.

The Ontario Superior Court of Justice has greenlit the plan of arrangement, which will see a subsidiary of ClinActiv acquire all outstanding common shares of Crescita. The transaction is expected to close in the second quarter of 2026, after which Crescita’s shares will be delisted from the Toronto Stock Exchange (TSX), ending its run as a publicly traded entity.

Shareholders are slated to receive a target price of $0.80 per share, though the final amount is subject to adjustments based on the company’s net working capital at closing. A floor price of $0.75 per share has been guaranteed, providing a concrete baseline for investors.

A Lucrative Exit for Shareholders

The acquisition was presented as a significant win for Crescita’s shareholders, a sentiment strongly validated by their overwhelming support. During a special meeting on May 14, 2026, investors voted decisively in favor of the arrangement. This support was hardly surprising given the financial terms of the offer.

The $0.80 target price represented a substantial premium of approximately 74% over the company's five-day volume-weighted average price on the TSX for the period ending March 13, 2026, the last trading day before the deal was initially announced. Such a premium provides immediate and certain value, an attractive proposition in volatile market conditions.

The company’s board of directors, following a recommendation from an independent special committee, had unanimously approved the deal, deeming it the “most favourable opportunity” for the company and its shareholders. Further cementing the deal's internal support, Crescita's directors and senior officers, who collectively controlled about 33% of the outstanding shares, had entered into voting agreements to back the transaction. The market had responded positively in the weeks leading up to the final approval, with Crescita’s stock (CTX) climbing 55.1% year-to-date as of mid-May.

ClinActiv's Strategic Play for a Global Platform

While the deal marks an exit for Crescita's public investors, it represents a foundational entrance for ClinActiv Holdings Inc. Describing itself as a “global dermatology and consumer health platform,” ClinActiv is executing a clear strategy of growth through targeted acquisitions. The company aims to build a portfolio of science-driven businesses with a footprint spanning North America, Europe, and China.

The acquisition of Crescita is a cornerstone of this strategy. ClinActiv’s leadership, including CEO Simon Dai and Head of International Business Watson Cheng, have signaled their intent to leverage what they call Crescita’s “differentiated and fully integrated platform.” This platform includes not just commercial products but also in-house research and development, manufacturing capabilities, and deep expertise in dermatology.

This move aligns perfectly with broader M&A trends in the 2026 healthcare landscape. Dermatology remains a hot sector for investors, particularly private equity-backed groups, due to its favorable reimbursement dynamics, high-margin cash-pay services, and scalable business models. By acquiring Crescita, ClinActiv gains immediate access to an established commercial infrastructure and a pipeline of intellectual property, which it plans to use as a springboard for further expansion and to unlock new opportunities through its global networks.

The Future of Crescita's Assets and Innovation

The central question arising from the acquisition is the fate of Crescita’s valuable assets. The company is known for its commercial prescription product Pliaglis®, a topical anesthetic, as well as a portfolio of non-prescription skincare products. Perhaps most valuable are its proprietary transdermal delivery platforms, such as Multiplexed Molecular Penetration Enhancers and DuraPeel, which are designed to facilitate the delivery of active ingredients through the skin.

According to the arrangement details, a post-closing reorganization is planned. ClinActiv will retain ownership of Crescita’s core commercial skincare and contract manufacturing business. However, certain “other parts of the company that the purchaser did not wish to acquire” will be sold to Crescita's senior management group on arm's length terms.

This division raises questions about the future of the company's R&D engine and its innovative delivery platforms. It is not explicitly clear whether these technological assets will remain with the commercial business under ClinActiv's control or be spun off with the management group. If ClinActiv integrates the technology, it could accelerate the development and global launch of new products. If the platforms are acquired by the management-led entity, it could lead to the formation of a new, highly focused R&D company. Industry observers will be watching closely for post-closing announcements from ClinActiv to understand the long-term strategic plan for these key innovations.

Navigating the Path to a Private Future

With both shareholder and court approvals secured, the path forward for Crescita is now a matter of execution. The company and ClinActiv will work to satisfy the remaining closing conditions, with the transaction expected to be finalized before the end of June 2026. The final per-share consideration will be announced publicly once the net working capital adjustments are calculated.

Immediately following the closing, Crescita will be delisted from the TSX and will apply to Canadian securities regulators to cease its status as a reporting issuer, relieving it of the obligations of public company disclosure. The arrangement agreement contains standard deal-protection measures, including a non-solicitation covenant and termination fees, underscoring the firm commitment from both parties to see the transaction through.

For Crescita Therapeutics, this acquisition marks the end of one chapter and the beginning of another. The company will transition from a public entity accountable to the wider market to a private asset within ClinActiv's growing global portfolio, fundamentally reshaping its future trajectory and the path to market for its dermatological innovations.